| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6127e235f50c58078b5c4ea00cb5f336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1ed4af9b73c5cb5066ea8a0f2d1f19a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16ce1bd40acf7777c7f02135e512c8c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99802129d921f4f53bed73b635603342 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate |
2010-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66d6fb6265914ce1311ba17bb1101c30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ca5021b220c3a8b102aa98363ddf6e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f39850c31f779086259e02c04a2192f |
| publicationDate |
2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012244132-A1 |
| titleOfInvention |
T-cell receptor |
| abstract |
The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10351824-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11014960-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113773378-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155784-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017258835-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11464853-B2 |
| priorityDate |
2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |